The US Patent and Trademark Office has announced the winners of its Patents for Humanity competition, which recognises patent owners and licensees addressing global health and development challenges.
Merck is the latest multinational pharma company to suffer a setback in India, after failing to win an injunction against generic versions of two anti-diabetes drugs.
India’s Supreme Court has rejected pharmaceutical company Novartis’s application to patent an updated version of its leukaemia drug Glivec, agreeing with the Comptroller General that it lacked novelty.
UK pharmaceutical company AstraZeneca has reached a settlement with Actavis and Egis Pharmaceuticals that delays the release of generic versions of its cholesterol treatment Crestor.
Pharmaceutical companies Bayer, Intendis and Intraserv have filed a patent infringement lawsuit against Glenmark after it applied to market a generic version of rosacea treatment Finacea.
Generic drug maker Mylan has struck a deal with pharma companies Shionogi and Andrx to resolve a patent dispute over their diabetes drug Fortamet.
Janssen Products, a subsidiary of Johnson & Johnson, has sued Indian pharmaceutical company Hetero Drugs for applying to market a generic version of its HIV treatment Prezista.
ViiV Healthcare, a public health joint venture between GlaxoSmithKline, Shionogi and Pfizer, has signed up to the Medicines Patent Pool (MPP) to provide greater access to affordable AIDS treatments in developing countries.
The US Food and Drug Administration has approved two generic versions of Reckitt Benckiser’s heroin replacement tablet Suboxone – despite Reckitt’s claims that the product is unsafe.
In a report published by Thomson Reuters on February 20, the BRICK nations were shown to be filing almost as many patents as the G7 nations in 2011.